Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.74 |
| ▸ | GAA | P10253 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | PARP1 | P09874 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 4/20 | 0.58 |
| ▸ | DRD3 | P35462 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399001 | 0.89 | PARP1 (0.78) | DRD4GAAALDH1A1PARP1TSHR | |
| SCHEMBL3399020 | 0.88 | DRD4 (0.63) | DRD4GAAALDH1A1PARP1TSHR | |
| SCHEMBL3397784 | 0.87 | GAA (0.59) | DRD4GAAALDH1A1PARP1TSHR | |
| SCHEMBL4812331 | 0.85 | DRD4 (1.00) | DRD4ALDH1A1DRD2DRD3HTR1A | |
| SCHEMBL3397948 | 0.84 | GAA (0.76) | DRD4GAAALDH1A1PARP1TSHR | |
| SCHEMBL3395090 | 0.82 | DRD4 (0.77) | DRD4GAAALDH1A1PARP1TSHR | |
| SCHEMBL6124919 | 0.82 | DRD4 (0.57) | DRD4GAAALDH1A1DRD2DRD3 | |
| SCHEMBL14585685 | 0.82 | GAA (0.78) | DRD4GAAALDH1A1TSHRHSD17B10 | |
| SCHEMBL3398034 | 0.81 | DRD4 (0.76) | DRD4GAAALDH1A1PARP1TSHR | |
| SCHEMBL3399004 | 0.81 | GAA (1.00) | DRD4GAAALDH1A1PARP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233472-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2014-01-15 | — | — | EP | claimed |
| EP-2233472-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2010-09-29 | — | — | EP | claimed |
| EP-2697206-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2019-04-03 | — | — | EP | disclosed |
| US-9353067-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2016-05-31 | — | — | US | disclosed |
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-20140296247-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-10-02 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| EP-2697206-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2014-02-19 | — | — | EP | disclosed |
| EP-2233472-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2014-01-15 | — | — | EP | disclosed |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2013-03-21 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| WO-2012140642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2012-10-18 | — | — | WO | disclosed |
| EP-2233472-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2010-09-29 | — | — | EP | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | PDE5A, PDE3B, PDE3A | DRD4 45/4885GAA 920/4885ALDH1A1 656/4885 |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | DRD4 53/4885GAA 654/4885ALDH1A1 976/4885 |
| US-20140296247-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | CYP19A1, HSD17B11, SHBG | DRD4 282/4885GAA 719/4885ALDH1A1 483/4885 |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | DRD4 45/4885GAA 920/4885ALDH1A1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.